"Preterm birth has a profound effect on babies and their families alike. CerviLenz provides an opportunity for improved management of this significant, unmet medical need, and I am personally committed to help reduce its incidence in the United States and abroad," said Koch.
According to Koch, more than one in eight pregnant women will deliver their baby preterm, which is defined as delivery before 37 completed weeks of gestation, and most often as a surprise to both the women and their physicians. The rate of preterm birth in the United States has increased over 30 percent since 1980; however, new research with progesterone is predicted to reverse this trend.
"In published work from the National Institutes of Health and others, progesterone therapy has been shown to reduce preterm birth risk, particularly in women with a short cervix," Koch continued. "Translating such groundbreaking work from the research setting to the real world will present many challenges. The CerviLenz device will help physicians, midwives and nurses to easily and cost effectively identify pregnant women at high risk of preterm birth and get them the care they need to reduce the risk of delivering their baby early."
The company is utilizing JumpStart's investment to help complete clinical studies, conduct additional market research, and engage in pre-launch marketing efforts.
This is JumpStart's 40th investment in its 29th company. Other healthcare companies in JumpStart's portfolio include AcelleRx Therapeutics, AnalizaDx, CardioInsight Technologies, Great Lakes Pharmaceuticals, Synapse Biomedical and Telerad Express.
About CerviLenz, Inc.
CerviLenz(TM), Inc., headquartered near Cleveland, Ohio, is a
manufacturer and marketer of a patented, FDA cleared device to predict
preterm birth risk in pregnant women by accurately measuring cervical
length. Preterm birth
|SOURCE JumpStart Inc.|
Copyright©2008 PR Newswire.
All rights reserved